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Large granular lymphocyte (LGL) leukemia is a rare clonal disease characterized by a persistent increase in the number of CD8+ cytotoxic T cells or CD16/56+ natural killer (NK) cells. 1 Patients are prone to recurrent infections and often suffer from severe cytopenias and autoimmune diseases that are thought to be mediated by cytotoxic LGL lymphocytes.
LGL leukemia is believed to begin as an antigen-driven immune response followed by the constitutive activation of cytotoxic T lymphocytes or NK cells. Overall, studies have highlighted the dysregulation of different apoptotic pathways (for example, sphingolipid and FAS/FAS ligand) and the activation of survival signaling pathways (for example, PI3K/AKT and RAS). 1 Previously, activating mutations in the Src-like homology 2 (SH2)-domain of the signal transducer and activator of transcription 3 (STAT3) gene were discovered in 40% of LGL leukemia patients. 2 These findings have later been validated in other cohorts, reporting STAT3 mutation frequency to be even up to 73% in selected patient groups. 3 Interestingly, aberrant STAT3 signaling is seen in almost all LGL leukemia patients, 4 indicating that the JAK/STAT pathway is activated through other mechanisms as well. In addition to LGL leukemia, activating somatic STAT3 mutations have recently been found in other diseases including T-, NK-and B-cell lymphomas, [5] [6] [7] hepatocellular adenomas 8 and chronic lymphoproliferative disorders of NK cells. 9 In a clinical phase II study, it was shown that the strongest activating STAT3 mutation, Y640F, predicted therapeutic response to immunosuppressive methotrexate in LGL leukemia, as all patients with this mutation responded to therapy after at least 4 cycles of methotrexate. 10 The diagnosis of T-LGL leukemia is often challenging as clinical symptoms and immunophenotypical findings bear a resemblance to other reactive conditions, making the distinction between clear malignant lymphoproliferation and reactive processes difficult. To discover novel genetic markers, we collected samples from LGL leukemia patients (n = 106) who were confirmed to have no STAT3 and STAT5 hotspot mutations in the SH2-domain by exome or amplicon sequencing. 11 Eighty eight patients had T-LGL leukemia Exome sequencing of seven LGL leukemia patients was performed on CD8+ T cells (tumor) and matched CD4+ T cells as control. The exome was captured with the Nimblegen SeqCap EZ Exome Library v2.0 and the sequencing was performed with the Illumina HiSeq2000 sequencing platform. Candidate somatic mutations were identified with a bioinformatics pipeline as described earlier. 2 In one of the seven patients analyzed, a novel STAT3 mutation was found outside the SH2-hotspot area (patient no. 1, Supplementary Table 1 ). This patient harbored a heterozygous missense mutation H410R in exon 13 of the DNAbinding domain (Supplementary Table 2 ). The variant allele frequency (VAF) was 49% in the CD8+ fraction and the H410R variant was not observed in the CD4+ fraction. The CD8+ population consisted of one major clone (vb.17: 95%) according to the TCR Vβ results (Figures 1a and b) . The H410 position is highly conserved and results in conversion of histidine to arginine (Figure 1c ), which would predict for a slight increase in hydrophilicity. Patient 1 also harbored a missense mutation P1324R in FANCA and a mutation giving rise to a truncated form of MLL2 (Q1893*; Supplementary Table 2 ). In the other six exome sequenced patient samples no additional novel STAT3 mutations were found (Supplementary Table 2 ).
As the mutation spectrum outside the SH2-domain hotspot in STAT3 has not been explored systematically before, we developed a targeted deep amplicon sequencing platform that allows for the sensitive analysis of all 23 coding exons of the STAT3 gene. A variant was called when variant base frequency was 0.5% of all reads covering a given position. Using this system, we sequenced mononuclear cell samples from 99 LGL leukemia patients previously confirmed to be STAT3 hotspot mutation negative. From these, three additional patients were discovered to have Table 1 ).
To explore the functional implications of the coiled-coil and DNA-binding domain mutations, we generated expression constructs for wild-type, F174S, S381Y, H410R and Y640F variants of the STAT3 protein. Luciferase measurements of sis-inducible response element reporter HEK-293 cells transfected with these constructs revealed a noticeable increase in both basal and IL6-stimulated transcriptional activation induced by the coiled-coil domain F174S and DNA-binding domain H410R variants were analyzed by Western blot with a phosphoSTAT3 specific antibody. Protein lysates of the different variants were separated on an SDSpolyacrylamide gel and transferred to a nitrocellulose membrane. STAT3 protein levels of the different variants were used to normalize for the transfection efficacy. β-Actin was used as a loading control. (c) Total RNA of the transfected HEK-293 cells was extracted and converted to cDNA using random primers. Expression levels of six known STAT3 target genes (SOCS3, JAK2, MYC, JUNB, BCL3 and CCL2) were measured and the results were normalized against four housekeeping genes (NONO, PGK-1, GAPDH and LDHA), which showed uniform expression across all samples. All reactions were run in triplicate wells and gene expression was quantified using the delta-delta Cq method.
compared with wild-type STAT3 (Figure 2a) . The S381Y variant on the other hand did not show a similar increase. The phosphorylation status of the variants was investigated with Western blotting and revealed F174S and H410R to induce a phosphorylation pattern comparable to the known activating Y640F SH2-domain mutation (Figure 2b) . However, the S381Y variant did not seem to be highly phosphorylated as the level of pSTAT3 was similar as seen with the wild-type STAT3. Furthermore, expression levels of six known STAT3 target genes were measured by quantitative PCR (Supplementary Table 3) , and SOCS3, CCL2, JUNB and BCL3 were revealed to be upregulated by the F174S, H410R and Y640F mutations but not by the S381Y variant when compared with the wild type (Figure 2c) .
The H410 position is highly conserved and results in conversion of histidine to arginine. Arginine residues within the DNA-binding domain of STAT3 have been found to promote intracellular shuttling and phosphorylation of STAT3. 12 An arginine-glutamine exchange at the STAT3 moieties R414 and R417 reduces cytokinedependent tyrosine phosphorylation of STAT3. The H410R variant seen in two LGL leukemia patients is located near this area and results in one extra arginine residue. It is plausible that this increase in hydrophilicity within the DNA-binding domain mediates the activation of STAT3. The other found mutation in the DNA-binding domain (S381Y) was not confirmed to be activating as no increased transcriptional activity, phosphorylation or increased expression of target genes was observed. Previously, patients with severe autoimmune diseases including type 1 diabetes and immunodysregulation polyendocrinopathy enteropathy X-linked-like syndrome were found to harbor activating heterozygous germline mutations in the DNA-binding domain. 13 The F174S coiled-coil domain mutation causes a conversion from hydrophobic, nonpolar phenylalanine to uncharged, polar serine. The coiled-coil domain has previously been shown to be essential in receptor binding mediated by the SH2-domain as well as subsequent activation. In concordance with our results, the α1 region encompassing amino acids 130-198 have been shown to be essential for STAT3 tyrosine phosphorylation as the deletion of α1 abolished tyrosine phosphorylation of STAT3 in EGF-induced COS-1 cells.
14 One possible mechanism for the involvement of the coiled-coil domain in STAT3 phosphorylation is through augmentation of the protein-protein interaction between STAT3 and the IL6 receptor during recruitment of STAT3 to the activated receptor following ligand binding. Mutations in the coiled-coil domain have previously been seen in patients with inflammatory hepatocellular adenomas where the E166Q mutant was shown to be constitutively phosphorylated on Tyr705, hypersensitive to IL6 stimulation and able to translocate to the nucleus. 8 Similarly in diffuse large B-cell lymphoma 15 the M206K STAT3 mutation was able to activate STAT3 signaling.
In conclusion, T-LGL leukemia patients without STAT3 SH2-domain mutations harbor novel activating mutations in the DNA-binding and coiled-coil domain of STAT3. The frequency of mutations was 3.8% (4 of 106 patients) in patients with no previously detected hotspot mutations in STAT3 or STAT5. These findings strengthen the evidence for a central role of STAT3 in the pathogenesis of LGL leukemia. Subsequently, the importance of screening the entire STAT3 gene in the diagnostic workup of LGL leukemia, as well as in other lymphoid malignancies where STAT3 mutations have previously been discovered, is further emphasized.
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HR has received honoraria from Novartis. SM has received honoraria and research funding from Novartis, Pfizer and Bristol-Myers Squibb. Paroxysmal nocturnal hemoglobinuria (PNH), a nonmalignant yet clonal disease that most often originates from hematopoietic stem cells (HSCs) with PIGA mutations, is characterized by intravascular hemolysis as a result of deficiency in glycosylphosphatidylinositolanchored proteins (GPI-APs) in erythrocytes and bone marrow failure. [1] [2] [3] [4] Additional mutations in genes such as HMGA2 and JAK2 in PIGA-mutant HSCs have been implicated in the extensive expansion of PNH clones. [5] [6] [7] However, the characteristics of HSCs with PIGA mutations that lead to secondary mutations and development of florid PNH are unknown. We recently treated a patient with PNH complicated by chronic myeloid leukemia (CML) using a tyrosine kinase inhibitor nilotinib alone that readily induced remission of both PNH and CML. Chronological analyses of the patient's GPI-AP − cells and BCR-ABL mRNA copy number provided insight into the origins of CML and PNH.
A 27-year-old woman with an unremarkable personal or family medical history was referred to our hospital for a closer examination of leukocytosis with anemia identified 7 months after parturition. A complete blood count performed 15 months earlier was normal. Laboratory findings on admission were as follows: white blood cell count of 18.7 × 10 9 /l with 1.7% stab neutrophils, 5.4% segmented neutrophils, 9.3% basophils, 1.3% promyelocytes, 5.0% myelocytes, 3.0% metamyelocytes, 18.0% lymphocytes and 0.7% blasts; hemoglobin (Hb) = 6.0 g/dl, platelets = 1000 × 10 9 /l, 20.0% reticulocytes, total/direct bilirubin = 1.9/0.3 mg/dl, lactate dehydrogenase (LDH) = 1963 IU/l and haptoglobin o 10 mg/dl. The direct Coombs test was negative. Urine test showed hemoglobinuria. Bone marrow examination revealed hypercellular marrow that had 37.6% erythroblasts and immature myeloid cells at various stages, including 0.8% myeloblasts. The karyotype was t(9;22)(q34;q11) in 20 of 20 dividing cells. BCR-ABL transcripts were amplified by reverse transcription-PCR. These findings were compatible with a diagnosis of CML in the chronic phase with a low Sokal score (0.78). Surprisingly, flow cytometry revealed that 99.2% of granulocytes and 75.7% of erythrocytes were negative for GPI-APs. The patient was thus diagnosed as having PNH complicated by CML. Administration of nilotinib at 600 mg/day was initiated in April 2013. On day 5 of treatment, the patient developed fatigue, nausea and vomiting with a high fever of 102.0°F. Blood test showed Hb = 4.3 g/dl, LDH = 4164 U/l and total bilirubin = 4.1 mg/dl. The exacerbation of intravascular hemolysis due to the rapid death of BCR-ABL-positive erythroblasts induced by nilotinib treatment was suspected. Nilotinib was discontinued on day 33 of treatment, and a transfusion of 280 ml of red blood cells and fluid therapy were given to ameliorate the clinical symptoms associated with massive hemolysis. Nilotinib was reinitiated at a dose of 400 mg/day after a 1-week washout period. Her peripheral blood counts and LDH levels gradually normalized thereafter without signs of hemolysis (Supplementary Figure 1) . She achieved a deep molecular response as defined by the international scale at 15 months of nilotinib therapy (Table 1 ). Blood samples were collected from the patient for the analyses of PIGA gene and GPI-AP after informed consent according to the protocols (R-89 and 876) approved by the ethics committees of Hyogo Cancer Center and Kanazawa University Graduate School of Medical Science. A blood sample was taken from a 59-year-old woman with florid PNH for the analysis of GPI-AP as reference.
We conducted PCR-based deep sequencing of all coding regions of the PIGA gene using primers tagged with NotI cleavage sites (Supplementary Table 1 ). Genomic DNA was extracted using Gentra Puregene Blood Kit (QIAGEN, Tokyo, Japan). Sequence data were generated on the Illumina Miseq platform (San Diego, CA, USA). Data processing and variant calling were performed as described previously. 8 Reagents and monoclonal antibodies used for detecting GPI-AP − cells are shown in Supplementary Table 2 . Six lineages of blood cells including granulocytes, erythrocytes, monocytes, T cells, B cells and natural killer (NK) cells were subjected to high-sensitivity flow cytometry for detecting small populations of GPI-AP − cells. All blood samples were analyzed within 24 h to avoid false positive results due to cell damage. Staining with each monoclonal antibody was performed according to the wellestablished lyse-stain protocol, previously described in detail. 9 The following cutoff values determined by our previous studies based on 183 A high-sensitivity flow cytometry analysis of the patient's peripheral blood at diagnosis revealed that 99.2% of granulocytes, 75.7% of erythrocytes and 99.3% of monocytes were GPI-AP − , whereas no T cells, B cells or NK cells had the PNH phenotype (Figure 1a ). This GPI-AP − cell distribution pattern was in sharp contrast to that of a patient with typical PNH who showed various percentages of GPI-AP − cells in all lineages of leukocytes and erythrocytes (Figure 1b) . Deep sequencing of leukocytes obtained at diagnosis showed a G279T (Q93H) mutation in exon 4 of the PIGA gene (Supplementary Figure 2) . The percentage of GPI-AP − cells rapidly decreased in response to nilotinib, and GPI-AP − granulocytes were 0.02% after 6 months of nilotinib therapy when the patient's BCR-ABL mRNA decreased to 0.007% (Table 1) . BCR-ABL mRNA declined to o 0.0035% 15 months after therapy; however, small populations of GPI-AP − granulocytes (0.01%) and erythrocytes (0.005%) were still detected at this time (Table 1 and Figure 1a ). The copy number of the mutant PIGA sequence in DNA of the patient's peripheral blood was determined by a digital PCR assay using the copy number of the wild-type PIGA sequence as an internal control. 11 The sequences of primers used for the PCR Accepted article preview online 6 October 2015; advance online publication, 23 October 2015
